Avery B Nathens

Dr. Avery B Nathens


Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

1 December 2017 in Annals of Surgery
Verified
Journal Article
Closed access
AAAziz S. Alali
Aziz S. Alali
KMKaushik Md Mukherjee
Kaushik Md Mukherjee
VMVictoria A. McCredie
Victoria A. McCredie
EGEyal MD Golan
Eyal MD Golan
PSPrakesh S. Md Shah
Prakesh S. Md Shah
MPMayur B. Md Patel
Mayur B. Md Patel
Objective: To determine if beta-(β)-blockers improve outcomes after acute traumatic brain injury (TBI). Background: There have been no new inpatient pharmacologic therapies to improve TBI outcomes in a half-century. Treatment of TBI patients with β-blockers offers a potentially beneficial approach. Methods: Using MEDLINE, EMBASE, and CENTRAL databases, eligible articles for our systematic review and meta-analysis (PROSPERO CRD42016048547) included adult (age ≥ 16 years) blunt trauma patients admitted with TBI. The exposure of interest was β-blocker administration initiated during the hospitalization. Outcomes were mortality, functional measures, quality of life, cardiopulmonary morbidity (e.g., hypotension, bradycardia, bronchospasm, and/or congestive heart failure). Data were analyzed using a random-effects model, and represented by pooled odds ratio (OR) with 95% confidence intervals (CI) and statistical heterogeneity (I2). Results: Data were extracted from 9 included studies encompassing 2005 unique TBI patients with β-blocker treatment and 6240 unique controls. Exposure to β-blockers after TBI was associated with a reduction of in-hospital mortality (pooled OR 0.39, 95% CI: 0.27–0.56; I2 = 65%, P < 0.00001). None of the included studies examined functional outcome or quality of life measures, and cardiopulmonary adverse events were rarely reported. No clear evidence of reporting bias was identified. Conclusions: In adults with acute TBI, observational studies reveal a significant mortality advantage with β-blockers; however, quality of evidence is very low. We conditionally recommend the use of in-hospital β-blockers. However, we recommend further high-quality trials to answer questions about the mechanisms of action, effectiveness on subgroups, dose-response, length of therapy, functional outcome, and quality of life after β-blocker use for TBI.

1 January 2015 in Injury
Verified
Journal Article
Closed access
MBM. Bawazeer
M. Bawazeer
NAN. Ahmed
N. Ahmed
HIH. Izadi
H. Izadi
AMA. McFarlan
A. McFarlan
ANAvery B Nathens
Avery B Nathens
KPK. Pavenski
K. Pavenski

1 April 2015 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Closed access
BHBarbara Haas
Barbara Haas
ADAristithes G. Doumouras
Aristithes G. Doumouras
DGDavid Gomez
David Gomez
CMCharles de Mestral
Charles de Mestral
DBDonald M. Boyes
Donald M. Boyes
ANAvery B Nathens
Avery B Nathens
BACKGROUND Injury surveillance is critical in identifying the need for targeted prevention initiatives. Understanding the geographic distribution of injuries facilitates matching prevention programs with the population most likely to benefit. At the population level, however, the geographic site of injury is rarely known, leading to the use of location of residence as a surrogate. To determine the accuracy of this approach, we evaluated the relationship between the site of injury and of residence over a large geographic area. METHODS Data were derived from a population-based, prehospital registry of persons meeting triage criteria for major trauma. Patients dying at the scene or transported to the hospital were included. Distance between locations of residence and of injury was calculated using geographic information system network analysis. RESULTS Among 3,280 patients (2005–2010), 88% were injured within 10 miles of home (median, 0.2 miles). There were significant differences in distance between residence and location of injury based on mechanism of injury, age, and hospital disposition. The large majority of injuries involving children, the elderly, pedestrians, cyclists, falls, and assaults occurred less than 10 miles from the patient’s residence. Only 77% of motor vehicle collision occurred within 10 miles of the patient’s residence. CONCLUSION Although the majority of patients are injured less than 10 miles from their residence, the probability of injury occurring “close to home” depends on patient and injury characteristics. LEVEL OF EVIDENCE Epidemiologic study, level III.

3 November 2020 in Journal of Trauma and Acute Care Surgery
Verified
Journal Article
Open access
GMGarrick Mok
Garrick Mok
RHRichard Hoang
Richard Hoang
MKMontaha Wajid Khan
Montaha Wajid Khan
DPDylan Pannell
Dylan Pannell
HPHenry T. Peng
Henry T. Peng
LLLuis Teodoro da Luz
Luis Teodoro da Luz
BACKGROUND: Treatment of acute trauma coagulopathy has shifted toward rapid replacement of coagulation factors with frozen plasma (FP). There are logistic difficulties in providing FP. Freeze-dried plasma (FDP) may have logistical advantages including easier storage and rapid preparation time. This review assesses the feasibility, efficacy, and safety of FDP in trauma. STUDY DESIGN AND METHODS: Studies were searched from Medline, Embase, Cochrane Controlled Trials Register, ClinicalTrials.gov, and Google Scholar. Observational and randomized controlled trials (RCTs) assessing FDP use in trauma were included. Trauma animal models addressing FDP use were also included. Bias was assessed using validated tools. Primary outcome was efficacy, and secondary outcomes were feasibility and safety. Meta-analyses were conducted using random-effect models. Evidence was graded using Grading of Recommendations Assessment, Development, and Evaluation profile. RESULTS: Twelve human studies (RCT, 1; observational, 11) and 15 animal studies were included. Overall, studies demonstrated moderate risk of bias. Data from two studies (n = 119) were combined for meta-analyses for mortality and transfusion of allogeneic blood products (ABPs). For both outcomes, no difference was identified. For mortality, pooled odds ratio was 0.66 (95% confidence interval, 0.29–1.49), with I 2 = 0%. Use of FDP is feasible, and no adverse events were reported. Animal data suggest similar results for coagulation and anti-inflammatory profiles for FP and FDP. CONCLUSION: Human data assessing FDP use in trauma report no difference in mortality and transfusion of ABPs in patients receiving FDP compared with FP. Data from animal trauma studies report no difference in coagulation factor and anti-inflammatory profiles between FP and FDP. Results should be interpreted with caution because most studies were observational and have heterogeneous population (military and civilian trauma) and a moderate risk of bias. Well-designed prospective observational studies or, preferentially, RCTs are warranted to answer FDP’s effect on laboratory (coagulation factor levels), transfusion (number of ABPs), and clinical outcomes (organ dysfunction, length of stay, and mortality). LEVEL OF EVIDENCE: Systematic review and meta-analysis, level IV.

15 August 2018 in Journal of Bone and Joint Surgery
Verified
Journal Article
Closed access
DPDaniel Pincus
Daniel Pincus
DWDavid Wasserstein
David Wasserstein
BRBheeshma Ravi
Bheeshma Ravi
AHAnjie Huang
Anjie Huang
JPJ. Michael Paterson
J. Michael Paterson
WWWalter Wodchis
Walter Wodchis
Background: Waiting for hip fracture surgery is associated with complications. The objective of this study was to determine whether waiting for hip fracture surgery is associated with health-care costs. Methods: We conducted a population-based, propensity-matched cohort study of patients treated between 2009 and 2014 in Ontario, Canada. The primary exposure was early hip fracture surgery, performed within 24 hours after arrival at the emergency department. The primary outcome was direct medical costs, estimated for each patient in 2013 Canadian dollars, from the payer perspective. The costs in the early and delayed groups were then compared using a difference-in-differences approach: the baseline cost in the year prior to the hip fracture that had been accrued by patients with early surgery was subtracted from the cost in the first year following the surgery (first difference), and the difference was then compared with the same difference among propensity-score-matched patients who had received delayed surgery (second difference). The secondary outcome was the postoperative length of stay (in days). Results: The study included 42,230 patients who received hip fracture surgery from a total of 522 different surgeons at 72 hospitals. The mean cost (and standard deviation) attributed to the hip fracture was $39,497 ± $46,645 per person. The matched patients who underwent surgery after 24 hours had direct 1-year medical costs that were an average of $2,638 higher (95% confidence interval [CI] = $1,595 to $3,680, p < 0.0001) and a postoperative length of stay that was an average of 0.610 day longer (95% CI = 0.1749 to 1.0331 days, p = 0.0058) compared with those who underwent surgery within 24 hours. Conclusions: Waiting >24 hours for hip fracture surgery was associated with increased medical costs and length of stay. Costs incurred by waiting may provide a financial incentive to mitigate delays in hip fracture surgery. Level of Evidence: Economic Level III. Please see Instructions for Authors for a complete description of levels of evidence.